Payden & Rygel’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $15.8M | Buy |
72,730
+15,720
| +28% | +$3.49M | 1.22% | 27 |
|
|
2025
Q4 | $13M | Sell |
57,010
-400
| -0.7% | -$91.1K | 0.9% | 40 |
|
|
2025
Q3 | $13.3M | Buy |
57,410
+57,300
| +52,091% | +$11.7M | 1.1% | 41 |
|
|
2025
Q2 | $20K | Sell |
110
-50,900
| -100% | -$9.46M | ﹤0.01% | 112 |
|
|
2025
Q1 | $10.7M | Buy |
51,010
+50,900
| +46,273% | +$9.9M | 0.92% | 58 |
|
|
2024
Q4 | $20K | Sell |
110
-4,900
| -98% | -$901K | ﹤0.01% | 122 |
|
|
2024
Q3 | $989K | Hold |
5,010
| – | – | 0.08% | 86 |
|
|
2024
Q2 | $859K | Hold |
5,010
| – | – | 0.07% | 86 |
|
|
2024
Q1 | $912K | Hold |
5,010
| – | – | 0.04% | 96 |
|
|
2023
Q4 | $776K | Hold |
5,010
| – | – | 0.05% | 103 |
|
|
2023
Q3 | $747K | Sell |
5,010
-117,730
| -96% | -$17.3M | 0.05% | 104 |
|
|
2023
Q2 | $16.5M | Sell |
122,740
-25,600
| -17% | -$3.75M | 1.17% | 35 |
|
|
2023
Q1 | $23.6M | Sell |
148,340
-59,930
| -29% | -$9.16M | 1.4% | 27 |
|
|
2022
Q4 | $33.7M | Sell |
208,270
-42,800
| -17% | -$6.56M | 1.79% | 15 |
|
|
2022
Q3 | $33.7M | Buy |
251,070
+4,500
| +2% | +$646K | 1.97% | 9 |
|
|
2022
Q2 | $37.8M | Buy |
246,570
+33,700
| +16% | +$5.15M | 2.27% | 6 |
|
|
2022
Q1 | $34.5M | Sell |
212,870
-137,540
| -39% | -$20M | 1.74% | 18 |
|
|
2021
Q4 | $47.4M | Buy |
350,410
+69,460
| +25% | +$8.2M | 2.19% | 3 |
|
|
2021
Q3 | $30.3M | Buy |
280,950
+89,150
| +46% | +$10.2M | 1.57% | 20 |
|
|
2021
Q2 | $21.6M | Sell |
191,800
-33,400
| -15% | -$3.76M | 1.03% | 57 |
|
|
2021
Q1 | $24.4M | Buy |
225,200
+13,000
| +6% | +$1.39M | 1.13% | 44 |
|
|
2020
Q4 | $22.7M | Sell |
212,200
-3,400
| -2% | -$327K | 1.17% | 46 |
|
|
2020
Q3 | $18.9M | Buy |
215,600
+7,100
| +3% | +$668K | 1.12% | 47 |
|
|
2020
Q2 | $20.5M | Hold |
208,500
| – | – | 1.3% | 41 |
|
|
2020
Q1 | $15.9M | Buy |
208,500
+15,700
| +8% | +$1.34M | 1.15% | 44 |
|
|
2019
Q4 | $17.1M | Buy |
192,800
+182,600
| +1,790% | +$15.2M | 1.07% | 43 |
|
|
2019
Q3 | $772K | Hold |
10,200
| – | – | 0.05% | 64 |
|
|
2019
Q2 | $742K | Hold |
10,200
| – | – | 0.05% | 73 |
|
|
2019
Q1 | $822K | Sell |
10,200
-128,300
| -93% | -$10.5M | 0.06% | 73 |
|
|
2018
Q4 | $12.8M | Sell |
138,500
-15,800
| -10% | -$1.39M | 1.03% | 50 |
|
|
2018
Q3 | $14.6M | Sell |
154,300
-10,800
| -7% | -$1.02M | 1.11% | 49 |
|
|
2018
Q2 | $15.3M | Buy |
165,100
+14,500
| +10% | +$1.42M | 1.2% | 44 |
|
|
2018
Q1 | $14.3M | Buy |
150,600
+16,200
| +12% | +$1.78M | 1.16% | 42 |
|
|
2017
Q4 | $13M | Hold |
134,400
| – | – | 1.13% | 48 |
|
|
2017
Q3 | $11.9M | Buy |
+134,400
| New | +$10.2M | 1.19% | 42 |
|
|
2016
Q1 | – | Sell |
-27,300
| Closed | -$1.62M | – | 148 |
|
|
2015
Q4 | $1.62M | Sell |
27,300
-191,600
| -88% | -$11M | 0.21% | 65 |
|
|
2015
Q3 | $11.9M | Hold |
218,900
| – | – | 1.71% | 26 |
|
|
2015
Q2 | $14.7M | Sell |
218,900
-52,600
| -19% | -$3.43M | 1.94% | 16 |
|
|
2015
Q1 | $15.9M | Buy |
271,500
+191,400
| +239% | +$11.6M | 2.07% | 11 |
|
|
2014
Q4 | $5.24M | Buy |
80,100
+2,500
| +3% | +$158K | 1% | 51 |
|
|
2014
Q3 | $4.48M | Sell |
77,600
-107,900
| -58% | -$5.99M | 0.89% | 51 |
|
|
2014
Q2 | $10.5M | Buy |
185,500
+69,600
| +60% | +$3.65M | 2.64% | 4 |
|
|
2014
Q1 | $5.96M | Hold |
115,900
| – | – | 2.32% | 10 |
|
|
2013
Q4 | $6.12M | Hold |
115,900
| – | – | 2.08% | 12 |
|
|
2013
Q3 | $5.18M | Sell |
115,900
-8,500
| -7% | -$377K | 1.85% | 13 |
|
|
2013
Q2 | $5.14M | Buy |
+124,400
| New | +$5.44M | 2.01% | 9 |
|
Other funds holding ABBV
VCM
VPM
Payden & Rygel's ABBV Position: Q1 2026 in Review
Payden & Rygel increased its AbbVie (ABBV) stake by 28% in Q1 2026, buying an estimated $3.49M and bringing the position to 72,730 shares worth $15.8M. The position accounts for 1.22% of the portfolio, ranked #27.
Payden & Rygel first reported a position in ABBV in Q2 2013 and has held it in 46 quarters since. The position peaked at $47.4M in Q4 2021. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Payden & Rygel held 72,730 shares of AbbVie worth $15.8M as of Q1 2026.
- Payden & Rygel bought 15,720 AbbVie shares in Q1 2026, an estimated $3.49M.
- AbbVie made up 1.22% of Payden & Rygel's portfolio in Q1 2026, its #27 holding.
- Payden & Rygel first reported a position in AbbVie in Q2 2013 and has held it in 46 quarters since.
- Payden & Rygel's AbbVie position peaked at $47.4M in Q4 2021.
- 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Payden & Rygel's 13F filing for Q1 2026, filed 12 May 2026.